Patient Dosing

Lyra's Mid-Stage Chronic Rhinosinusitis Candidate Study Progressed, Shares Fall

Emergent Shares Decline Following Commencement Of Initial-Stage Lassa Virus Vaccine Candidate Study

Werewolf Shares Climb As Initial-Stage Solid Tumors Study Kicks-off

Emergent Shares Decline Following Commencement Of Initial-Stage Lassa Virus Vaccine Candidate Study

Werewolf Shares Climb As Initial-Stage Solid Tumors Study Kicks-off

Geron Commences Initial-Stage Rare Blood Cancer Combination Study

Kronos Bio Shares Fall After Initial-Stage Blood Cancer Study Takes-off

Geron Commences Initial-Stage Rare Blood Cancer Combination Study

Kronos Bio Shares Fall After Initial-Stage Blood Cancer Study Takes-off

Graphite Bio Shares Soar As Initial-Stage Blood Cell Disorder Study Launched

Passage Bio Commences Initial-Stage Brain Disorder Study

Patient Dosing Recent News

Aerie Shares Gain Following Patient Dosing In Late-Stage Dry Eye Disease Study

Aerie Pharmaceuticals (NASDAQ: AERI) has initiated patient dosing in the Phase 3 registrational COMET-3 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED).

Capricor Initiates Late-Stage Neuropsychiatric Disorder Study

Capricor Therapeutics (NASDAQ: CAPR) initiated dosing of first patient in HOPE-3, a Phase 3 clinical trial investigating CAP-1002 for treating late-stage Duchenne muscular dystrophy (DMD).

Impel Commences Mid-Stage Autism Spectrum Disorder Study

Impel Pharmaceuticals (NASDAQ: IMPL) has dosed the first patient in a Phase 2a proof-of-concept study of INP105, nasal olanzapine, a widely used atypical, second-generation antipsychotic.

Pulmatrix Commences Initial-Stage Acute Migraine Study

Pulmatrix (NASDAQ: PULM) has dosed first subject in its Phase 1 trial evaluating PUR3100 for the treatment of acute migraine. PUR3100 is an orally-inhaled Dihydroergotamine (DHE) acute migraine therapy.

Synlogic Initiates Initial-Stage Homocystinuria Study

Synlogic (NASDAQ: SYBX) has dosed its first healthy volunteer in its Phase 1 study of the investigational oral therapy SYNB1353 for the potential treatment of homocystinuria (HCU).

Immunocore Commences Initial-Stage HIV Study

Immunocore Holdings (NASDAQ: IMCR) has dosed the first patient in the first-in-human Phase 1 clinical trial of IMC-M113V for the treatment of patients with human immunodeficiency virus (HIV) infection.

Calithera Commences Mid-Stage Study Of DLBCL Candidate

Calithera Biosciences, Inc. (NASDAQ: CALA) initiates dosing first patient in the phase 2 clinical trial evaluating its spleen tyrosine kinase (SYK) inhibitor mivavotinib (CB-659) in patients with relapsed/refractory non-germinal center B-cell like (non-GCB) diffuse large B-cell lymphoma (DLBCL).

Biomea Fusion Commences Initial-Stage Study For Plasma Cell Cancer Setting

Biomea Fusion (NASDAQ: BMEA) has dosed the the first patient in the multiple myeloma (MM) cohort of the Phase I clinical trial evaluating BMF-219, a covalent menin inhibitor. Multiple myeloma (MM) is a cancer of plasma cells, which make antibodies (immunoglobulins) and are mainly located in the bone marrow.